214
Views
8
CrossRef citations to date
0
Altmetric
Perspective

Anticytokine therapy, particularly anti-IFN-γ, in Th1-mediated autoimmune diseases

, &
Pages 11-25 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Bo Xie, Yuqi Zhu, Yuqing Shen, Wen Xu & Xiuzu Song. (2023) Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection. Expert Opinion on Therapeutic Targets 27:3, pages 189-206.
Read now

Articles from other publishers (7)

Yifei Feng & Yan Lu. (2022) Advances in vitiligo: Update on therapeutic targets. Frontiers in Immunology 13.
Crossref
Farinaz Behfarjam, Mohammad Hossein Sanati, Zohreh Jadali, Zahra Soheila Soheili, Siavash Nasseri Moghaddam, Mitra Ataei & Sepideh Nikfam. (2018) IFN-γ siRNA Effectively Knocked Down IFN-γ Gene Expression and Reduced Cytokine Secretion in Peripheral Blood Mononuclear Cells of Patients with Autoimmune Hepatitis. Hepatitis Monthly 18:8.
Crossref
Antoine Dufour, Caroline L. Bellac, Ulrich Eckhard, Nestor Solis, Theo Klein, Reinhild Kappelhoff, Nikolaus Fortelny, Parker Jobin, Jacob Rozmus, Jennifer Mark, Paul Pavlidis, Vincent Dive, Sean J. Barbour & Christopher M. Overall. (2018) C-terminal truncation of IFN-γ inhibits proinflammatory macrophage responses and is deficient in autoimmune disease. Nature Communications 9:1.
Crossref
Kevin H. Toomer & Zhibin Chen. (2014) Autoimmunity as a Double Agent in Tumor Killing and Cancer Promotion. Frontiers in Immunology 5.
Crossref
Stephen C. Pflugfelder, Rosa M. Corrales & Cintia S. de Paiva. (2013) T helper cytokines in dry eye disease. Experimental Eye Research 117, pages 118-125.
Crossref
SIMON SKURKOVICH & BORIS SKURKOVICH. (2005) Anticytokine Therapy, Especially Anti-Interferon-γ, as a Pathogenetic Treatment in TH-1 Autoimmune Diseases. Annals of the New York Academy of Sciences 1051:1, pages 684-700.
Crossref
S.V Skurkovich, B Skurkovich & J.A Kelly. (2002) Anticytokine therapy – new approach to the treatment of autoimmune and cytokine-disturbance diseases. Medical Hypotheses 59:6, pages 770-780.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.